Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChAd155-RSV Vaccine in Infants
NCT03636906Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2019
- Primary completion
- Jan 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 13
01
Overview
A Phase 2 trial of ChAd155-RSV in respiratory syncytial virus infection (RSV), sponsored by GSK. Started Apr 2019; status: completed.
02
Drugs
ChAd155-RSV
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03636906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03636906.